Cullinan Oncology, LLC Contracts & Agreements
46 Contracts & Agreements
- Business Finance (11 contracts)
- Business Formation (1)
- Business Operations (9)
- Human Resources (15)
- Intellectual Property (3)
- Mergers & Acquisitions (1)
- Real Estate (1)
- Uncategorized (5)
- Employment Agreement, effective April 29, 2024, between Cullinan Therapeutics, Inc. and Mary Kay Fenton (Filed With SEC on April 29, 2024)
- Form of Pre-Funded Warrant (Filed With SEC on April 16, 2024)
- Form of Registration Rights Agreement, dated April 15, 2024, by and among Cullinan Therapeutics, Inc. and the purchasers party thereto (Filed With SEC on April 16, 2024)
- Form of Stock Purchase Agreement, dated April 15, 2024, by and among Cullinan Therapeutics, Inc. and the purchasers party thereto (Filed With SEC on April 16, 2024)
- Form of Restricted Stock Unit Award Agreement (Filed With SEC on March 14, 2024)
- Amendment No. 1 to Employment Agreement, by and between the Registrant and Nadim Ahmed (Filed With SEC on November 8, 2023)
- Non-Employee Director Compensation Policy (Filed With SEC on August 10, 2023)
- Consulting Agreement, dated June 8, 2023, by and between the Registrant and Patrick Baeuerle (Filed With SEC on August 10, 2023)
- License and Collaboration Agreement, dated February 13, 2023, by and between the Registrant and Harbour BioMed US Inc (Filed With SEC on May 11, 2023)
- Exchange Agreement, dated January 17, 2023, by and among Cullinan Oncology, Inc. and the Stockholders named therein (Filed With SEC on January 19, 2023)
- Separation Agreement, effective as of October 18, 2021, by and between the Registrant and Owen Hughes (Filed With SEC on March 17, 2022)
- Employment Agreement, effective February 28, 2022, between Cullinan Oncology, Inc. and Jeffrey Jones (Filed With SEC on March 3, 2022)
- Employment Agreement, effective as of October 18, 2021, by and between the Company and Nadim Ahmed (Filed With SEC on October 18, 2021)
- Consulting Agreement, dated May 20, 2021, among the Registrant and Jon Wigginton, M.D (Filed With SEC on August 10, 2021)
- Description of Securities (Filed With SEC on March 30, 2021)
- Registration Rights Agreement, dated January 7, 2021, among the Registrant and certain of its stockholders (Filed With SEC on March 30, 2021)
- Form of Underwriting Agreement (Filed With SEC on January 4, 2021)
- Services Agreement, by and between the Company and Patrick Baeuerle (Filed With SEC on January 4, 2021)
- Form of Contribution Agreement by and between Cullinan Oncology, LLC and Cullinan Management, Inc (Filed With SEC on January 4, 2021)
- 2021 Employee Stock Purchase Plan (Filed With SEC on January 4, 2021)
- 2021 Stock Option and Incentive Plan and form of award agreements thereunder (Filed With SEC on January 4, 2021)
- Form of Registration Rights Agreement, among the Registrant and certain of its stockholders, to be in effect immediately prior to completion of this offering (Filed With SEC on January 4, 2021)
- Form of Agreement and Plan of Merger by and between Cullinan Oncology, LLC and Cullinan Management, Inc (Filed With SEC on January 4, 2021)
- License Agreement, dated December 24, 2020, by and between Cullinan Pearl Corp. and Zai Lab (Shanghai) Co., Ltd (Filed With SEC on December 28, 2020)
- Specimen Common Stock Certificate (Filed With SEC on December 28, 2020)
- Senior Executive Cash Incentive Bonus Plan (Filed With SEC on December 18, 2020)
- Third Amended and Restated Limited Liability Company Agreement, dated December 16, 2020, by and among Cullinan Oncology, LLC and its members (Filed With SEC on December 18, 2020)
- Form of Indemnification Agreement, between the Registrant and each of its directors (Filed With SEC on December 18, 2020)
- Form of Indemnification Agreement, between the Registrant and each of its executive officers (Filed With SEC on December 18, 2020)
- Exclusive Patent License Agreement, dated December 12, 2019, as amended on April 3, 2020, by and between Massachusetts Institute of Technology and Cullinan Amber Corp (Filed With SEC on December 18, 2020)
- Collaboration Agreement, dated November 28, 2018, by and between Adimab, LLC and Cullinan Management, Inc (Filed With SEC on December 18, 2020)
- License and Collaboration Agreement, dated February 4, 2019, by and between Taiho Pharmaceutical, Co., Ltd. and Cullinan Pearl Corp (Filed With SEC on December 18, 2020)
- Exclusive License Agreement, dated August 31, 2020, by and among Deutsches Krebsforschungszentrum, Eberhard Karls University of Tuebingen, Faculty of Medicine, Universittsmedizin... (Filed With SEC on December 18, 2020)
- Offer Letter, dated June 16, 2017, by and between Cullinan Management, Inc. and Leigh Zawel (Filed With SEC on December 18, 2020)
- Offer Letter, dated May 1, 2017, by and between Cullinan Management, Inc. and Owen Hughes (Filed With SEC on December 18, 2020)
- Offer Letter, dated August 25, 2020, by and between Cullinan Management, Inc. and Jeffrey Trigilio (Filed With SEC on December 18, 2020)
- Form of Executive Employment Agreement (Filed With SEC on December 18, 2020)
- Consulting Agreement, dated January 1, 2019, by and between Cullinan Management, Inc. and Corinne Savill (Filed With SEC on December 18, 2020)
- Consulting Agreement, dated January 1, 2019, by and between Cullinan Management, Inc. and Patrick Baeuerle (Filed With SEC on December 18, 2020)
- Consulting Agreement, dated April 1, 2020, by and between Cullinan Management, Inc. and Globeways Holdings Limited (Filed With SEC on December 18, 2020)
- Sublease, effective as of December 14, 2017, by and between Teva Pharmaceuticals USA, Inc. and Cullinan Management, Inc (Filed With SEC on December 18, 2020)
- Form of Voting Agreement (Filed With SEC on December 18, 2020)
- Form of Investors Rights Agreement (Filed With SEC on December 18, 2020)
- Form of Services Agreement (Filed With SEC on December 18, 2020)
- Form of Royalty Transfer Agreements (Filed With SEC on December 18, 2020)
- Non-Employee Director Compensation Policy (Filed With SEC on December 18, 2020)
